CCNB1, CDK1, and RRM2 have been reported to be enriched in the p53 signaling pathway and are believed to act as potential biomarkers and therapeutic targets for hepatitis B virus-associated hepatocellular carcinoma [52]. Here, CDK1 is linked to hepatocellular carcinoma.